Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease (IBIM-Park)
Sponsor: France Parkinson Association
Terminated
Despite an extension of the planned duration of inclusion and an enrolled patient number inferior than planned, coordinating investigator considered that it was more reasonable to stop inclusions in order to analyze the data already available
Other Parkinson's Disease trials with similar outcome
Listed as NCT04652843, this NA trial focuses on Parkinson's Disease and remains terminated or withdrawn. Sponsored by France Parkinson Association, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Jun 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2024 — Jul 2024 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2024 — Mar 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2022 — Jan 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2022 [monthly]
Not Yet Recruiting NA
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- France Parkinson Association
- Institut National de la Santé Et de la Recherche Médicale, France
- Luxia Scientific
- Nantes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .